| Formulary Chapter 3: Respiratory system - Full Section
|
Notes:
Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand. |
| Useful Links |
 ANHSFT AWC CCG Joint Stable COPD Treatment Algorithm v4 |
 Asthma guidance (BTS / SIGN. 2016) |
|
Bradford District and Craven Adult Asthma Guideline |
|
Bradford District and Craven Inhaler Options for Asthma |
|
Drug Safety Update: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects |
|
Inhaler technique guides (from Asthma UK) |
|
NICE CG101: Chronic obstructive pulmonary disease in over 16s: diagnosis and management (June 2010) |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
03.01 |
Bronchodilators (0,0)
|
|
03.01.01 |
Adrenoceptor agonists (0,0)
|
|
03.01.01.01 |
Selective Beta2 agonists (0,0)
|
|
|
Short-acting beta2 agonists
(2,0)
|
|
|
Long-acting beta2 agonists
(4,0)
|
|
03.01.01.02 |
Other adrenoceptor agonists (0,0)
|
|
03.01.02 |
Antimuscarinic bronchodilators
(5,0)
|
|
03.01.03 |
Theophylline
(2,0)
|
|
03.01.04 |
Compound bronchodilator preparations
(4,0)
|
|
03.01.05 |
Peak flow meters, inhaler devices and nebulisers
(1,0)
|
|
|
Peak flow meters
(2,0)
|
|
|
Drug delivery devices
(4,0)
|
|
|
Nebulisers (0,0)
|
|
|
Nebuliser Diluent (0,0)
|
|
03.02 |
Corticosteroids
(11,0)
|
|
03.03 |
Cromoglicate, related therapy and leukotriene receptor antagonists (0,0)
|
|
03.03.01 |
Cromoglicate and related therapy (0,0)
|
|
|
Related therapy (0,0)
|
|
03.03.02 |
Leukotriene receptor antagonists
(1,0)
|
|
03.03.03 |
Phosphodiesterase type-4 inhibitors
(1,0)
|
|
03.04 |
Antihistamines, hyposensitisation, and allergic emergencies (0,0)
|
|
03.04.01 |
Antihistamines (0,0)
|
|
|
Non-sedating antihistamines
(3,0)
|
|
|
Sedating antihistamins
(5,0)
|
|
03.04.02 |
Allergen Immunotherapy
(0,1)
|
|
|
Omalizumab
(3,0)
|
|
03.04.03 |
Allergic emergencies
(1,0)
|
|
|
Anaphylaxis
(1,0)
|
|
|
Angioedema (0,0)
|
|
|
Intramuscular adrenaline (epinephrine) (0,0)
|
|
|
Intravenous adrenaline (epinephrine) (0,0)
|
|
|
Self-administration of adrenaline (epinephrine)
(1,0)
|
|
03.05 |
Respiratory stimulants and pulmonary surfactants (0,0)
|
|
03.05.01 |
Respiratory stimulants
(1,0)
|
|
03.05.02 |
Pulmonary surfactants
(1,0)
|
|
03.06 |
Oxygen
(1,0)
|
|
|
Long-term oxygen therapy (0,0)
|
|
|
Short burst oxygen therpary (0,0)
|
|
|
Ambulatory oxygen therapy (0,0)
|
|
|
Oxygen therapy equipment (0,0)
|
|
|
Arrangements for supplying oxygen (0,0)
|
|
03.07 |
Mucolytics
(2,0)
|
|
|
Dornase alfa (0,0)
|
|
|
Hypertonic Sodium Chloride (0,0)
|
|
03.08 |
Aromatic inhalations (0,0)
|
|
03.09 |
Cough preparations (0,0)
|
|
03.09.01 |
Cough suppressants
(1,0)
|
|
|
Palliative care (0,0)
|
|
03.09.02 |
Expectorant and demulcent cough preparations
(1,0)
|
|
03.10 |
Systemic nasal decongestants (0,0)
|
